Join
Live feed
·
PRReleasevia Quantisnow
Cybin Inc. logo

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

ByQuantisnow·Wall Street's wire, on your screen.
CYBN· Cybin Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CYBN (Cybin Inc.) and more on Quantisnow.